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Abstract
Drug and alcohol use have been associated with a worse prognosis in short-term and cross-
sectional analyses of HIV-infected populations, but longitudinal effects on adherence to
antiretroviral therapy (ART) and clinical outcomes in advanced AIDS are less well characterized.
We assessed self-reported drug and alcohol use in AIDS patients, and examined their association
with non-adherence and death or disease progression in a multicenter observational study. We
defined non-adherence as reporting missed ART doses in the 48 hours before study visits. The
association between drug use and ART non-adherence was evaluated using repeated measures
generalized estimating equation (GEE) models. The association between drug and alcohol use and
time to new AIDS diagnosis or death was evaluated via Cox regression models, controlling for
covariates including ART adherence. Of 643 participants enrolled between 1997–1999 and
followed through 2007, at entry 39% reported ever using cocaine, 24% amphetamines, and 10%
heroin. Ongoing drug use during study follow-up was reported by 9% using cocaine, 4%
amphetamines, and 1% heroin. Hard drug (cocaine, amphetamines, or heroin) users had 2.1 times
higher odds (p=0.001) of ART non-adherence in GEE models and 2.5 times higher risk (p=0.04)
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of AIDS progression or death in Cox models. Use of hard drugs was attenuated as a risk factor for
AIDS progression or death after controlling for non-adherence during follow-up (HR=2.11,
p=0.08), but was still suggestive of a possible adherence-independent mechanism of harm. This
study highlights the need to continuously screen and treat patients for drug use as a part of
ongoing HIV care.
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INTRODUCTION
Adherence to antiretroviral therapy (ART) is crucial to optimize treatment efficacy and
prolong survival in patients with HIV disease [1–3]. The longitudinal effect of alcohol and
illicit substance use (hereafter, “drug use”) on adherence to highly active antiretroviral
therapy (HAART) and on clinical outcomes in patients with advanced AIDS has been less
well characterized.
Drug and alcohol use are highly prevalent among HIV-infected populations in the United
States [4]; but the long-term impact of these substances among patients on HAART is
unclear [5–9]. Drug and alcohol use have been associated with decreased use of HAART
[10–15], non-adherence to HAART [14–20], decreased viral suppression [14,21–24], and
HIV disease progression in cross-sectional and short-term analyses of HIV-infected
populations [6,15,16,19,22,23,25,26]. Active drug use was linked to disease progression in a
university-based HIV-infected population, followed for up to 21/2 years from a single clinic
[24]. Even intermittent use of intravenous drugs was associated with diminished virologic
response to HAART in a population with lower HIV severity [14]. Recent heroin or cocaine
use and homelessness were associated with increased short-term mortality in HIV-infected
patients with alcohol problems [27]. Little is known about the prevalence of drug and
alcohol use and its impact on morbidity and mortality over longer periods or after prolonged
immune reconstitution.
The objective of this study is to describe the prevalence and impact of self-reported alcohol
and drug use in patients enrolled in a decade-long clinical trial of AIDS patients who
experienced immune reconstitution on therapy. We assessed the impact of reported drug and
alcohol use on self-reported adherence to antiretroviral medications and on HIV disease




In the clinical trial, we enrolled 643 HIV-infected subjects without prior Mycobacterium
avium complex (MAC) and with documented immune reconstitution (CD4 cell counts <50
followed by CD4 >100 cells/mm3 on two separate occasions before study entry) from
October 1997 through April 1999. AIDS Clinical Trials Group (ACTG) 362, a prospective,
placebo-controlled multicenter trial of discontinuing MAC prophylaxis, was stopped in
October 1999 after failing to show a treatment difference for azithromycin versus placebo.
We enrolled 433 of the participants still on study in an observational cohort to evaluate
cardiovascular, metabolic, and neurological outcomes of HAART therapy [28]. Self-
administered questionnaires were used to assess alcohol and drug use at entry and during
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follow-up visits among participants [26]. The protocol and its successive amendments were
approved by institutional review boards at 29 participating U.S. ACTG sites; all participants
provided written informed consent.
Data Collection and Event Definitions
Subjects were assessed at baseline, weeks 4 and 8, and then at 8–32 week intervals through
the end of the study at week 512. They were evaluated for alcohol and drug use, medication
adherence, new opportunistic infections or cardiovascular events, interval medical histories,
CD4 counts, plasma HIV-1 RNA measurements, and any changes in ART or other
medications. HIV-1 RNA measurements were obtained using the Roche Amplicor standard
assay (Roche Diagnostics, Branchburg, NJ), with a lower limit of quantification of 500
copies/mL.
Data was collected from October 1997 to April 2007 on ART use before and at study entry
and throughout the follow-up period. Individual clinical events and specific diagnoses were
reviewed and corroborated using the Adult ACTG Criteria for Clinical Events by study
clinicians (SEC, SLK, JSC) [29].
Adherence Assessment
At each follow-up visit, subjects were asked whether they were prescribed and adhering to
ART. Non-adherence to ART was defined as missing any doses during the prior 48 hours. In
addition, we defined “ever non-adherent” to ART if the subject reported ever missing ART
in the past week at baseline or in the prior 48 hours at any follow-up visit throughout the
study.
At baseline, participants completed a self-report questionnaire to assess potential factors
affecting adherence [30]. Baseline adherence was assessed based on this question: “When
was the last time you skipped any of your medications?” with the options “within the past
week,” ”within the past 2 weeks,” “2–4 weeks ago,” “1–3 months ago,” “more than 3
months ago,” and “never skip medications or not applicable.” The responses to this question
were grouped as “within the past week” versus “more than a week ago” (i.e., any of last 5
options) to be most similar to the 2-day adherence assessment.
Assessment of Drug and Alcohol Use
At each visit, subjects completed a self-reported questionnaire describing their current use of
alcohol, cocaine (or crack), heroin, and amphetamines, and whether they were in methadone
treatment. Patients reported their quantity and frequency of their alcohol consumption
during the past 30 days. Drinking was dichotomized in 2 ways, as heavy drinkers (regularly
drinking >4 drinks per day on average when they drank over the past 30 days) or not; and as
binge drinkers (5 or more drinks within a couple of hours at least once in the last 30 days) or
not [16,31]. Ongoing use of cocaine, heroin, and/or amphetamines within 30 days prior to a
study visit was referred to as “ongoing hard drug use.” Participants were also asked whether
or not they injected cocaine, amphetamines or heroin in the past 30 days, and frequency of
use per day. They reported whether they had ever used cocaine, amphetamines and heroin at
baseline and throughout the study, and alcohol use in the 30 days prior to each visit.
Statistical Analysis
Non-adherence to ART over the prior two days and recent substance use over the prior 30
days were assigned to the nearest scheduled study visit, at weeks 0 and 4, at 8 week intervals
from weeks 8 to 224,, and at 16–32 week intervals from week 224 to 512. The association
between drug use and non-adherence to ART was evaluated using repeated measures
generalized estimating equation (GEE) models, with an assumption of equal correlation
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between any pair of visits within each participant. The repeated measures models considered
the indicator of recent hard drug use and non-adherence for each study visit. Other possible
predictors of non-adherence included demographic factors (e.g. age, sex, race/ethnicity),
HIV disease severity (baseline viral load, baseline CD4 count, Karnofsky score<80, prior
AIDS defining condition), and treatment indicators (years of combination ART at entry,
randomization to azithromycin or placebo). We performed backward selection of candidate
predictors for multivariable models, retaining covariates with p<0.10.
The association between drug and alcohol use and time to new AIDS diagnosis or death was
evaluated via Cox regression models, controlling for the potential confounders described
above along with ART non-adherence. Two approaches for controlling for non-adherence
were considered: one which controlled only for recent non-adherence to ART in the week
prior to study entry (i.e., baseline non-adherence), and a second approach using time-
updated indicators of ART non-adherence during study follow-up (time-dependent non-
adherence). The association between ART non-adherence and virologic treatment failure
(HIV-1 RNA ≥ 500 copies/mL) was evaluated in two ways. First, non-adherence was
evaluated as a time-dependent covariate in a Cox model for time to first viral load failure.
Second, non-adherence immediately prior to each visit was evaluated as a correlate of
virologic failure at that visit in a GEE repeated measures analysis. All analyses were
performed using Statistical Analysis System 9.1 (SAS Institute, Cary, NC). P-values less
than 0.05 were considered statistically significant.
RESULTS
Subject characteristics
The demographic and clinical characteristics of the 643 participants are presented in Table
1. All subjects were on ART at baseline. Subjects had an average of 11 visits (IQR=5–16) at
which adherence and drug and alcohol use were assessed. Maximum time on study was 9.4
years and median time on study was 6.0 years (IQR=1.9–8.6). The rate of loss to follow up
was approximately 6% per year during the first two years of the clinical trial and less than
3% per year during the last 7 years of the observational study. Of the 643 subjects, 434
completed the clinical trial, 53 died during study follow-up, 17 were at sites that lost funding
to continue the study, and 144 were lost to follow-up (81 refused contact, 51 were unable to
be contacted, 4 moved, 1 was incarcerated, and 7 discontinued due to other reasons). The
144 lost to follow-up were more likely to be younger and black or Hispanic rather than
white non-Hispanic, but were similar in other baseline characteristics (gender, CD4 count,
HIV-1 RNA, adherence, ART use, and lifetime drug use or alcohol use reported in the 30
days prior to entry).
Of the 53 deaths during the study, 28 were determined to be non-HIV associated, 10 were
HIV-associated, 4 were other disease processes, and 11 were of unknown causes. Seventy
AIDS-related events occurred over the course of the study, half of which were
microscopically or histologically confirmed. The vast majority were opportunistic infections
including 15 with esophageal candidiasis, 14 with Pneumocystis jiroveci pneumonia, 7 with
cytomegalovirus disease and 6 with cryptosporidiosis. There were 4 confirmed cases of
MAC disease and 7 with HIV wasting syndrome. Only 5 developed HIV-associated
malignancies, 3 with Kaposi’s sarcoma and 2 with lymphoma.
Incidence and prevalence of drug and alcohol use
At baseline, 253 (39%) reported ever having used cocaine, 154 (24%) amphetamines and 65
(10%) heroin. Only 28 (2%) reported ever having used methadone treatment at baseline.
Ninety-nine patients (15%) reported ever having injected drugs at baseline. While on study,
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6 patients (0.9%) reported having injected cocaine, 4 (0.6%) amphetamines, and 3 (0.5%)
heroin, with 1 (0.2%) having recently injected more than one drug within 30 days of a study
visit. Baseline drug use in the participants who enrolled in the observational study was
similar to those who did not continue (data not shown).
During the study, 9% reported having used cocaine, 4% amphetamines, 1% heroin, and 4%
methadone treatment in the past 30 days prior to study entry or any subsequent study visit
(See Table 1). Of the 77 patients who used hard drugs in the 30 days prior to study entry or
any study visit, only 8 (11%) were new users who had not reported using hard drugs prior to
entry.
At baseline, of the 373 patients who reported use of alcohol in the prior 30 days (58%), 31
(8%) were heavy drinkers and 119 (32%) were binge drinkers. During the study, 102 (16%)
patients were classified as heavy drinkers and 276 (43%) were classified as binge drinkers.
Most of the patients classified as heavy drinkers were also binge drinkers (97%) but only a
third of binge drinkers were also classified as heavy drinkers (36%). Of those who reported
being heavy or binge drinkers during the study, 69 (68%) had reported not being heavy
drinkers, and 151 (55%) were not binge drinkers in the 30 days prior to their baseline visit
(See Table 1).
Current or prior IV drug use, heavy or binge drinking, and non-adherence to ART were
significantly associated with hard drug use during the study (Table 1). At any visit, the
maximum prevalence of reporting binge drinking was 19% and hard drug use was<5% (See
Figure 1). Figure 1 depicts the percentage of heavy and binge alcohol use and drug use
through the study with reported non-adherence to ART by week.
ART non-adherence
At baseline, 15% of participants reported ART non-adherence during the prior week (Figure
1). While on study, reported ART non-adherence at any one visit ranged from 5 to 12%.
Overall, the percentage of patients who reported ART non-adherence at least once between
baseline and the end of study follow-up, e.g., “ever non-adherent,” was 49% (316). We
found each additional decade of age was associated with a 25% decrease in odds of non-
adherence (adjusted OR=0.75, p<0.001), using repeated measures GEE models. The odds of
non-adherence increased slightly over the study follow-up (OR=1.02 per 24 weeks, p=0.03).
Association of drug and alcohol use with ART non-adherence
In multivariable GEE analyses adjusting for age, sex, and correlation among visits for each
subject, hard drugs users had 2.14 times higher odds (95% CI: 1.36, 3.38, p<0.001) of ART
non-adherence compared to non-users (see Table 2). In addition, those who recently used
cocaine had 2.60 times higher odds (95% CI: 1.63, 4.13, p<0.001) and those who recently
used methadone had 2.33 times higher odds than non-users (95% CI: 1.16, 4.69, p=0.02).
Heavy drinking was not associated with non-adherence, but binge drinking was associated
with a 1.53 times higher odds (95% CI: 1.21, 1.95, p<0.01) of ART non-adherence.
Association of non-adherence with AIDS progression or death
Of the 55 subjects with new AIDS diagnoses during the study, 15 subsequently died. In
multivariate Cox proportional hazards models adjusting for potential confounders, there was
no association of baseline ART non-adherence with risk of AIDS or death (adjusted
HR=0.78, 95% CI=0.50,1.21, p=0.26) (See Table 3). However, time-updated measures of
non-adherence during the study were associated with an almost two-fold increase in the odds
of developing an AIDS condition or death (adjusted HR=1.84, 95% CI=1.15,2.94, p=0.01).
COHN et al. Page 5













Association of drug and alcohol use with AIDS progression or death
The association between drug and alcohol use and a new AIDS diagnosis or death was
evaluated via Cox regression models, controlling for covariates with and without adjustment
for non-adherence (See Table 3). After controlling for baseline VL and Karnofsky Score,
hard drug users had 2.46 times higher risk (p=0.04) of a new AIDS outcome or death. When
we controlled for baseline adherence in addition, use of hard drugs was associated with a
significant increase in risk of an AIDS outcome or death (adjusted HR=2.58, p=0.03).
However, when we controlled for adherence as a time-dependent covariate throughout study
follow-up, risk from hard drug use was attenuated (adjusted HR=2.11, p=0.08). Neither
binge drinking nor heavy drinking was found to increase the risk of an AIDS outcome or
death when controlling for baseline VL and Karnofsky score.
In Cox regression models for time to death, the effect of hard drug use was associated with a
3-fold higher risk after adjusting for age, baseline RNA>500 copies/mL, and Karnofsky
score ≤80 (adjusted HR=3.09, p=0.03), but no association was found for alcohol use.
Association of non-adherence with virologic treatment failure (VTF)
Non-adherence was associated with VTF (e.g. HIV-1 RNA ≥500 copies/ml) when evaluated
as time-dependent non-adherence in a Cox regression model controlled for baseline hard
drug use (adjusted HR=1.42, p=0.004). Likewise, non-adherence at each visit correlated
with VTF at that visit in a GEE repeated measured analysis adjusted for recent hard drug
use, visit week, age, sex, and correlation among visits for a given participant (adjusted
OR=1.41, p<0.001). In this GEE model, we found that recent hard drug use was also
significantly associated with VTF (adjusted OR=1.63, p=0.002).
DISCUSSION
Our study patients with advanced AIDS who had responded to HAART had a high
prevalence of drug and alcohol use. Almost 40% of participants reported a history of hard
drug use and 12% reported some ongoing use during the study. Similarly, over half reported
recent use of alcohol, with 43% reporting binge drinking during the study. These data are in
keeping with statistics on alcohol and drug use in HIV-infected persons in care for HIV in
the United States [10,16], and are significantly higher than those found in the general
population [32].
Our findings are consistent with previous studies that have found that active drug use is
associated with non-adherence to HAART and incomplete viral suppression when actively
using drugs [14,16,17]. Adherence to ART is essential to decrease the incidence of
opportunistic infections and improve the overall outcomes of patients with HIV. Our study
used a self-reported measure of adherence that has been used successfully throughout the
ACTG and many other HIV clinical trials. This adherence measure predicted AIDS
progression and death in the first year of follow-up of this study [26]. In the current analysis,
hard drug users had higher odds of developing a new AIDS-related condition or dying, even
after controlling for adherence. Similar to findings from a four year observational study of
illicit drug users in Baltimore by Lucas et al., we found that drug users, had a two-fold
higher risk of developing new opportunistic conditions or death after adjusting for HAART
use and time-dependent adherence [17].
Although drug users may have been excluded from clinical trials in the past, more recent
ACTG studies exclude subjects only if, in the opinion of the investigator, active drug or
alcohol use would interfere with adherence to study requirements. Thus, compared with
AIDS patients in care, patients on this trial were probably less likely to use drugs and
alcohol. Those who used alcohol may also have been more likely to admit to drinking >4
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drinks on one occasional despite drinking more than that, leading to underreporting of
“heavy drinking” in this study. Reporting binge drinking has previously been shown to be
associated with ART nonadherence [20,33], although its impact on clinical outcomes
warrants further investigation.
Drug and alcohol use may increase the risk of AIDS progression and death through direct
biological effects and/or indirect behavioral effects [17]. In vitro, opioids impair lymphocyte
function [34] and increase HIV-1 replication in mononuclear cells [35]. Drug use may also
increase HIV replication mediated through effects on immune activation [36]. Cocaine
appears to promote HIV infection in vivo, interacting with host immunity, cell susceptibility
and activating sigma-1 receptors [37]. Drug use may also affect the immune system and
other host defenses that may predispose to OI-related morbidity and mortality. For example,
smoking tobacco, which is frequently associated with drug use, is a risk factor for
developing cryptococcal infections in AIDS [38]. Alcohol, in addition to smoking, may
paralyze respiratory cilia function and predispose users to recurrent bacterial pneumonias
[39,40]. Carrico et al. found that compared to non-users, weekly stimulant use (cocaine and
methamphetamines) was associated with higher HIV viral loads, higher neopterin levels, a
measure of immune activation, and lower tryptophan levels [41].
Cohorts of injection drug users in the pre-HAART era had similar rates of CD4 lymphocyte
decline [42] and progression of AIDS compared with men who have sex with men [43].
Moore et al. found that HIV-infected drug users had similar risk of disease progression in
the pre-HAART era but had higher rates of disease progression in the HAART era compared
to non-drug users [17,44], suggesting that non-adherence may account for much of the
difference
Our study had several limitations. Patients who achieve immunorestoration and choose to
participate in a decade long observational study are likely atypical of other AIDS patients.
Research volunteers have been shown to be less impulsive, more satisfied, and more positive
than the general population [45]. As a result of this self-selection, our participants may
under-represent the true prevalence of drug and alcohol abuse among patients with HIV in
clinical practice and consequently, may have a lower likelihood of using illicit substances
and alcohol than the average patient with HIV/AIDS on HAART in clinical practice.
Patients who use drugs and alcohol may be more likely to underreport their drug use, miss
study visits or prematurely discontinue the study compared to non-users; drug users tend to
minimize or deny drug use and are more likely to discontinue HAART or the clinical trial if
they were using drugs. Misclassification from this underreporting would reduce the power of
our study.
We did not assess lifetime use of alcohol or tobacco, or other potential covariates such as
homelessness, depression, health literacy, hepatitis status, insurance status, and recruitment
and retention strategies used. Although self-reported measures of drug use are useful, we
probably underestimated the use of drugs by not performing more other objective measures
of drug use such as urine drug screening. We also did not ask about other drugs of abuse
including amyl nitrates, marijuana, recreational use of prescription drugs or other drugs
considered to be “party drugs.”
This study of patients with advanced AIDS who had responded to HAART and were
followed for close to ten years found a high prevalence of alcohol and drug use. Binge
drinking and drug use was associated with increased risk of non-adherence that only
partially explained poorer virologic control and increased risk of progression of AIDS or
death. Our study highlights the need to routinely and continuously screen all patients with
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HIV for current drug and alcohol use, and to offer alcohol and drug treatment services and
other targeted interventions where appropriate to optimize HIV management and outcomes.
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Figure 1. Percent of AIDS Patients in ACTG 362 Self-Reporting Drug Use1 and Non-Adherence2
During Study Follow-up
1 Hard drug use: defined as reporting drug use within 30 days prior to entry or prior to any
study visit.
2 Non-adherence: defined as missing any antiretroviral therapy within the past week prior to
entry or in the past 2 days at any study visit.
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Table 2
Association between Hard Drug Use and Non-Adherence based on GEE Repeated Measures Models
Adjusting for Within-Participant Correlation among Multiple Study Visits
Substance Use1 Adjusted Odds Ratio2 95% Confidence Interval P-value
Recent Cocaine Use 2.60 (1.63, 4.13) <0.001
Recent Heroin Use 1.94 (0.39, 9.58) 0.42
Recent Amphetamine Use 1.79 (0.73, 4.39) 0.20
Recent Methadone Treatment 2.33 (1.16, 4.69) 0.02
Recent Hard Drug Use (Cocaine, Amphetamine, or Heroin) 2.14 (1.36, 3.38) 0.001
Heavy Drinking 1.19 (0.72, 1.98) 0.50
Binge Drinking 1.53 (1.21, 1.95) <0.001
1
Defined as reported use in the 30 days prior to a visit.
2
Each row represents a separate model for the specified substance use, adjusted for visit week, age, sex, and correlation among visits for a given
participant.
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Table 3
Association between Hard Drug Use and Risk of AIDS Progression or Death based on Cox Models for Time
to Event
Recent Substance Use at Entry1 Adjusted Hazard Ratio2 95% Confidence Interval P-value
Without adjusting for non-adherence:
 Recent Hard Drug Use (Cocaine, Heroin, or Amphetamine) 2.46 (1.06, 5.69) 0.04
 Baseline Viral Load > 500 copies/mL 2.12 (1.38, 3.26) <0.001
 Karnofsky Score ≤ 80 2.01 (1.23, 3.28) 0.005
Adjusting for non-adherence reported at study entry:
 Recent Hard Drug Use (Cocaine, Heroin, or Amphetamine) 2.58 (1.11, 5.97) 0.03
 Baseline Viral Load > 500 copies/mL 2.14 (1.39, 3.30) <0.001
 Karnofsky Score ≤ 80 2.07 (1.27, 3.39) 0.004
 Non-adherence reported at entry 0.78 (0.50, 1.21) 0.26
Adjusting for non-adherence reported throughout study follow-up as time-dependent covariate:
 Recent Hard Drug Use (Cocaine, Heroin, or Amphetamine) 2.11 (0.90, 4.92) 0.08
 Baseline Viral Load > 500 copies/mL 1.92 (1.24, 2.97) 0.003
 Karnofsky Score ≤ 80 1.93 (1.18, 3.15) 0.01
 Time-updated Non-Adherence 1.84 (1.15, 2.94) 0.01
1
Defined as reported use in the 30 days prior to study entry.
2
We adjusted for baseline HIV RNA>500 copies/ml and Karnofsky score only since all other covariates (age, sex, baseline CD4, non-white status,
randomized treatment status [azithromycin versus placebo], years on antiretroviral therapy at entry, and prior AIDS defining event) had p>0.20 or
higher.
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